S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
Average 126% gains – NO losers!?   (Ad)pixel
Why Invest in High-Yield Dividend Stocks?
The 2 Dow Stocks with Decade-Long Win Streaks on the Line
3 Stable Growth Stocks for Bumpy Times
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
One Stock Is All You Need  (Ad)pixel
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
Average 126% gains – NO losers!?   (Ad)pixel
Why Invest in High-Yield Dividend Stocks?
The 2 Dow Stocks with Decade-Long Win Streaks on the Line
3 Stable Growth Stocks for Bumpy Times
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
One Stock Is All You Need  (Ad)pixel
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
Average 126% gains – NO losers!?   (Ad)pixel
Why Invest in High-Yield Dividend Stocks?
The 2 Dow Stocks with Decade-Long Win Streaks on the Line
3 Stable Growth Stocks for Bumpy Times
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
One Stock Is All You Need  (Ad)pixel
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
Average 126% gains – NO losers!?   (Ad)pixel
Why Invest in High-Yield Dividend Stocks?
The 2 Dow Stocks with Decade-Long Win Streaks on the Line
3 Stable Growth Stocks for Bumpy Times
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
One Stock Is All You Need  (Ad)pixel
NASDAQ:FGEN

FibroGen - FGEN Stock Forecast, Price & News

$14.05
-0.42 (-2.90%)
(As of 08/11/2022 12:00 AM ET)
Add
Compare
Today's Range
$13.87
$14.64
50-Day Range
$8.91
$14.60
52-Week Range
$7.81
$16.91
Volume
738,531 shs
Average Volume
881,835 shs
Market Capitalization
$1.31 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00

FibroGen MarketRank™ Forecast

Analyst Rating
Hold
1.50 Rating Score
Upside/​Downside
43.1% Downside
$8.00 Price Target
Short Interest
Healthy
5.80% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.18
Upright™ Environmental Score
News Sentiment
0.53mentions of FibroGen in the last 14 days
Based on 20 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.39) to ($2.12) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.52 out of 5 stars

Medical Sector

1035th out of 1,112 stocks

Pharmaceutical Preparations Industry

502nd out of 544 stocks

FGEN stock logo

About FibroGen (NASDAQ:FGEN) Stock

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. StockNews.com lowered shares of FibroGen from a "buy" rating to a "hold" rating in a report on Wednesday. The Goldman Sachs Group cut their price objective on shares of FibroGen from $9.00 to $8.00 and set a "sell" rating on the stock in a report on Tuesday, May 24th.

FibroGen Stock Up 2.5 %

NASDAQ:FGEN opened at $14.47 on Thursday. The firm's fifty day simple moving average is $11.63 and its two-hundred day simple moving average is $12.01. FibroGen has a 12-month low of $7.81 and a 12-month high of $16.91.

FibroGen (NASDAQ:FGEN - Get Rating) last released its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.78) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.94) by $0.16. FibroGen had a negative net margin of 83.64% and a negative return on equity of 100.51%. The business had revenue of $29.81 million for the quarter, compared to analyst estimates of $36.15 million. During the same period in the previous year, the company earned ($1.45) earnings per share. The business's revenue for the quarter was up 22.3% on a year-over-year basis. On average, analysts predict that FibroGen will post -3.39 earnings per share for the current fiscal year.

Receive FGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for FibroGen and its competitors with MarketBeat's FREE daily newsletter.

FGEN Stock News Headlines

FibroGen (NASDAQ:FGEN) Stock Rating Lowered by StockNews.com
Recap: FibroGen Q2 Earnings - Benzinga
FibroGen Reports Second Quarter 2022 Financial Results
Preview: FibroGen's Earnings
FibroGen (NASDAQ:FGEN) Lifted to Buy at StockNews.com
See More Headlines
Receive FGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for FibroGen and its competitors with MarketBeat's FREE daily newsletter.

FGEN Company Calendar

Last Earnings
8/08/2022
Today
8/11/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:FGEN
Employees
566
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.00
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
-43.1%
Consensus Rating
Hold
Rating Score (0-4)
1.50
Research Coverage
2 Analysts

Profitability

Net Income
$-290,020,000.00
Pretax Margin
-84.11%

Debt

Sales & Book Value

Annual Sales
$235.31 million
Book Value
$1.33 per share

Miscellaneous

Free Float
90,667,000
Market Cap
$1.31 billion
Optionable
Optionable
Beta
0.87

Key Executives

  • Mr. Enrique A. Conterno (Age 55)
    CEO & Director
    Comp: $1.31M
  • Mr. Juan Graham (Age 46)
    Chief Financial Officer
    Comp: $377.44k
  • Dr. Elias Kouchakji (Age 66)
    Sr. VP of Clinical Devel., Drug Safety & Pharmacovigilance
  • Ms. Christine L. Chung (Age 54)
    Sr. VP of China Operations
    Comp: $1.01M
  • Mr. Thane Wettig (Age 57)
    Chief Commercial Officer
    Comp: $709.39k
  • Dr. Mark Eisner M.D. (Age 56)
    M.P.H., Chief Medical Officer
    Comp: $1.87M
  • Dr. Barry A. Berkowitz Ph.D.
    Founder
  • Dr. John J. Hunter Ph.D. (Age 59)
    Chief Scientific Officer
  • Ms. Karen L. Bergman
    VP of Investor Relations & Corp. Communications
  • Mr. Michael D. Lowenstein J.D.
    Ph.D., Chief Legal Officer













FGEN Stock - Frequently Asked Questions

Should I buy or sell FibroGen stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for FibroGen in the last twelve months. There are currently 1 sell rating and 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" FGEN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FGEN, but not buy additional shares or sell existing shares.
View FGEN analyst ratings
or view top-rated stocks.

What is FibroGen's stock price forecast for 2022?

2 Wall Street analysts have issued twelve-month price targets for FibroGen's stock. Their FGEN share price forecasts range from $8.00 to $8.00. On average, they anticipate the company's share price to reach $8.00 in the next twelve months. This suggests that the stock has a possible downside of 43.3%.
View analysts price targets for FGEN
or view top-rated stocks among Wall Street analysts.

How have FGEN shares performed in 2022?

FibroGen's stock was trading at $14.10 at the beginning of the year. Since then, FGEN shares have increased by 0.1% and is now trading at $14.12.
View the best growth stocks for 2022 here
.

When is FibroGen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our FGEN earnings forecast
.

How were FibroGen's earnings last quarter?

FibroGen, Inc. (NASDAQ:FGEN) issued its earnings results on Monday, August, 8th. The biopharmaceutical company reported ($0.78) EPS for the quarter, beating the consensus estimate of ($0.94) by $0.16. The biopharmaceutical company had revenue of $29.81 million for the quarter, compared to analyst estimates of $36.15 million. FibroGen had a negative net margin of 83.64% and a negative trailing twelve-month return on equity of 100.51%. The company's quarterly revenue was up 22.3% on a year-over-year basis. During the same quarter in the previous year, the company earned ($1.45) EPS.

What other stocks do shareholders of FibroGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other FibroGen investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Aegean Marine Petroleum Network (ANW), NIC (EGOV), Gran Tierra Energy (GTE), Allergan (AGN) and ALJ Regional (ALJJ).

When did FibroGen IPO?

(FGEN) raised $146 million in an IPO on Friday, November 14th 2014. The company issued 8,100,000 shares at $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners acted as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.

What is FibroGen's stock symbol?

FibroGen trades on the NASDAQ under the ticker symbol "FGEN."

Who are FibroGen's major shareholders?

FibroGen's stock is owned by many different institutional and retail investors. Top institutional shareholders include Assenagon Asset Management S.A. (1.04%), Pictet Asset Management SA (0.33%), Swiss National Bank (0.22%), Walleye Capital LLC (0.20%), Pinnacle Associates Ltd. (0.18%) and JPMorgan Chase & Co. (0.15%). Insiders that own company stock include Christine Chung, Enrique A Conterno, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Thane Wettig, Thomas B Neff and Thomas F Kearns Jr.
View institutional ownership trends
.

How do I buy shares of FibroGen?

Shares of FGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is FibroGen's stock price today?

One share of FGEN stock can currently be purchased for approximately $14.12.

How much money does FibroGen make?

FibroGen (NASDAQ:FGEN) has a market capitalization of $1.32 billion and generates $235.31 million in revenue each year. The biopharmaceutical company earns $-290,020,000.00 in net income (profit) each year or ($2.37) on an earnings per share basis.

How many employees does FibroGen have?

The company employs 566 workers across the globe.

How can I contact FibroGen?

FibroGen's mailing address is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. The official website for the company is www.fibrogen.com. The biopharmaceutical company can be reached via phone at (415) 978-1200, via email at ir@fibrogen.com, or via fax at 415-978-1902.

This page (NASDAQ:FGEN) was last updated on 8/12/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.